In conclusion, our study demonstrated that HDAC2 could promote OA through miR-503-5p/SGK1 axis, which might function as a therapeutic target for OA treatment.
In conclusion, our study demonstrated that HDAC2 could promote OA through miR-503-5p/SGK1 axis, which might function as a therapeutic target for OA treatment.Bilateral congenital diaphragmatic hernia (CDH) is very rare. A few studies have reported the pathogenic role of 5p in CDH.
A 23-year-old primigravida Japanese woman was referred for the following abnormal findings at 33 weeks of gestation polyhydramnios, macroglossia, talipes equinovarus, and levocardia. A marker chromosome was detected by amniocentesis. Fluorescence in situ hybridization with whole chromosome paint 5 and nucleolus organizer region probes confirmed its origin from chromosome 5 and an acrocentric chromosome. The karyotype of the fetus was diagnosed as 47, XY, +mar. ish +mar(WCP5+). At 39 + 5 weeks, a 2462 g male infant was delivered, with a specific facial configuration. Bilateral CDH, hypoplasia of the corpus callosum, atrial septal defect, and hypothyroidism were also detected in the baby. The karyotype of the peripheral blood was consistent with that of the amniocentesis.
Genes coded on 5p might be associated with the pathogenesis of CDH; however, further investigation is required.
Genes coded on 5p might be associated with the pathogenesis of CDH; however, further investigation is required.Hypermagnesemia can be a fatal condition and should be diagnosed early on. Most reports of hypermagnesemia have been of adults with impaired renal function. We describe the case of a pediatric patient without renal dysfunction who developed severe hypermagnesemia.
A healthy 20-month-old Asian girl presented to our emergency department with episodes of vomiting and a reduced level of consciousness. The neurological examination showed a symmetric decrease in muscle tone, and the deep tendon reflexes were decreased. https://www.selleckchem.com/products/jzl184.html On admission, her magnesium (Mg) level was 11.0 mg/dL after receiving magnesium oxide for 4 days because of constipation. She was immediately administered calcium gluconate infusion (3.9 mEq), and then was continuously infused with it (0.23 mEq/h) as a Mg antagonist to cardiac side effects. She was kept hydrated with 0.9% sodium chloride to maintain good urine output to excrete the Mg. The level of the serum Mg decreased to 2.4 mg/dL, enabling her to regain consciousness. During 5 years of follow-up, she was neurologically well, without the recurrence of hypermagnesemia.
Even in the absence of significant renal dysfunction, the prescription of a laxative containing Mg for constipation can result in severe hypermagnesemia. In addition, the symptoms of hypermagnesemia are nonspecific, and early diagnosis is difficult unless it is actively suspected.
Even in the absence of significant renal dysfunction, the prescription of a laxative containing Mg for constipation can result in severe hypermagnesemia. In addition, the symptoms of hypermagnesemia are nonspecific, and early diagnosis is difficult unless it is actively suspected.The most common histopathologic malignant and benign nodules are Adenocarcinoma and Granuloma, respectively, which have different standards of care. In this paper, we propose an automatic framework for the diagnosis of the Adenocarcinomas and the Granulomas in the CT scans of the chest from a private dataset. We use the radiomic features of the nodules and the attached vessel tortuosity for the diagnosis. The private dataset includes 22 CTs for each nodule type, i.e., adenocarcinoma and granuloma. The dataset contains the CTs of the non-smoker patients who are between 30 and 60 years old. To automatically segment the delineated nodule area and the attached vessels area, we apply a morphological-based approach. For distinguishing the malignancy of the segmented nodule, two texture features of the nodule, the curvature Mean and the number of the attached vessels are extracted.
We compare our framework with the state-of-the-art feature selection methods for differentiating Adenocarcinomas from Granulomas. These methods employ only the shape features of the nodule, the texture features of the nodule, or the torsion features of the attached vessels along with the radiomic features of the nodule. The accuracy of our framework is improved by considering the four selected features.
We compare our framework with the state-of-the-art feature selection methods for differentiating Adenocarcinomas from Granulomas. These methods employ only the shape features of the nodule, the texture features of the nodule, or the torsion features of the attached vessels along with the radiomic features of the nodule. The accuracy of our framework is improved by considering the four selected features.Due to improved imaging sensitivity, the term "oligometastatic" prostate cancer disease is diagnosed more often, leading to an increasing interest in metastasis-directed therapy (MDT). There are two types of radiation based MDT applied when treating oligometastatic disease (1) stereotactic body radiation therapy (SBRT) generally used for bone metastases; or (2) SBRT for isolated nodal oligometastases combined with prophylactic elective nodal radiotherapy. This review aims to summarize current evidence data, which may shed light on the optimal management of this heterogeneous group of patients.
A systematic review of the Medline database through PubMed was performed according to PRISMA guidelines. All relevant studies published up to November 2020 were identified and screened. Fifty-six titles were included. Besides outcome parameters, different prognostic and predictive factors were assessed, including site of metastases, time between primary treatment and MDT, use of systemic therapies, hormone sensitivistate cancer. Prospective studies are under way and will provide further high-level evidence.
To our best knowledge this review on oligometastatic prostate cancer included the largest number of original articles. It demonstrates the therapeutic potential and challenges of MDT for oligometastatic prostate cancer. Prospective studies are under way and will provide further high-level evidence.